On November 10, 2017, Calyx Bio-Ventures Inc. (TSXV:CYX) closed the transaction. The company issued 14,857,143 units for gross proceeds of CAD 1,040,000 in the transaction. The transaction included participation from 24 placees including, three from aggregate pro group for 600,000 shares, Adrian Bak: director of the company for 300,000 shares and Graeme Watson; director of the company for 100,000 shares. The securities issued are subject to hold period expiring on March 11, 2018. The company paid sales commission of CAD 2,100 to Leede Jones Gable Inc. in the transaction. TSX Venture Exchange has accepted for filing documentation with respect to the transaction.